High sensivity C-reactive protein as a complement to classical methods in the evaluation of coronary event's risk;hsCRP (białko C-reaktywne oznaczane metoda̧ o dużej czułości) jako uzupełnienie klasycznych metod oceny ryzyka wysta̧pienia epizodu wieńcowego

Polski Merkuriusz Lekarski

Volumn 20, Issue 118, 2006, Pages 448-452

  Markuszewski, Leszek ^a   Pietruszyński, Robert ^a   Wojdyn, Marcin ^a   Retelewska, Weronika ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular event's risk (CVE); hsCRP; Ischaemic heart disease

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVASCULAR RISK; ISCHEMIC HEART DISEASE; MEDICAL PRACTICE; MEDICAL RESEARCH; REVIEW; RISK ASSESSMENT;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; HUMANS; PROGNOSIS; RISK ASSESSMENT;

EID: 33646677481     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Albert M.A., Danielson E., Rifai N. i wsp.: For the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001, 286, 64-7015.
2. Bassuk S.S., Rifai N., Ridker P.M.: High-sensitivity C-reactive protein: clinical importance. Curr. Probl. Cardiol., 2004, 29(8), 439-493.
3. Cybulska B., Adamus J., Bejnarowicz J. i wsp.: Profilaktyka choroby niedokrwiennej serca. Rekomendacje Komisji Profilaktyki Polskiego Towarzystwa Kardiologicznego. 2000, 3-4, 13-14.
4. Cummings K.C.: Coronary artery disease and high-sensitivity C-reactive protein. Physicians Reference Laboratory, March 2002, www.prlnet.com/HSCRP.htm
5. Danesh J., Wheeler J.G., Hirschfield G.M. i wsp.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med., 2004, 350, 1387-1397.
6. Dunn F.G., McLenachan J., Isles G.G. i wsp.: Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. J. Hypertens., 1990, 8, 775-82.
7. Grundy S.M., Pasternak R., Greenland P. i wsp.: AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. JACC, 1999, 34(4), 1348-1359.
8. Hubert N.B., Feinleib M., McNamara P.M. i wsp.: Obesity is an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart study. Circulation, 1983, 67, 968-977.
9. Levy D., Salomon M., D'Agostino R.B. i wsp.: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 1994, 90, 1786-1793.
10. Lindahl B., Toss H., Siegbahn A. i wsp.: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. N. Engl. J. Med., 2000, 343, 1139-1147.
11. Lindmark E., Diderholm E., Wallentin L. i wsp.: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA, 2001, 286, 2107-2113.
12. Neaton J., Wentworth D.: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. The Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med., 1992, 152, 56-64.
13. Padwal R., Straus S.E., McAlister F.A.: Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ, 2001, 21, 322(7292), 977-980.
14. Pasternak R.C., Grundy S.M., Levy D., Thompson PD.: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. JACC, 1996, 27(5), 978-990.
15. Prescott E., Hippe M., Schnohr P. i wsp.: Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ, 1998, 316, 1043-1047.
16. Pyorala K., De Backer G., Graham I. i wsp.: Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Cardiology, 1996, 41(2), 149-182.
17. Ridker P.M., Brown N.J., Vaughan D.E. iwsp.: Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, 2004, 109, IV-6 -IV-19.
18. Ridker P.M., Buring J.E., Cook N.R. i wsp.: C-reactive protein, the meta-bolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation, 2003, 107, 391-397.
19. Rifai N., Ridker P.M.: Clin High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Chem., 2001, 47(3), 403-411.
20. Ridker P.M., Rifai N., Cook N.R. i wsp.: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA, 2005, 20, 294(3), 326-333.
21. Ridker P.M., Rifai N., Rose L. i wsp.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med., 2002, 347, 1557-1565.
22. Sandvik L., Erikssen J., Thaulow E. i wsp.: Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N. Engl. J. Med., 1993, 328, 533-537.
23. Sattar N., Gaw A., Scherbakova O. i wsp.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 2003, 108, 414-419.
24. Tice J.A., Browner W., Tracy R.P. i wsp.: The relation of C-reactive protein levels to total and cardiovascular mortality in older U. S. women. Am. J. Med., 2003, 114, 199-205.
25. Torres J.L., Ridker P.M.: Clinical use of high-sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr. Opin. Cardiol., 2003, 18, 471-478.
26. Wilson P.W., D'Agostino R., Levy D. i wsp.: Prediction of coronary heart disease using risk factor categories. Circulation, 1998, 97, 1837-1847.
27. Winter R.J., Koch K.T., van Straalen J.P. i wsp.: C-reactive protein and coronary events following percutaneous coronary angioplasty. Am. J. Med., 2003, 115, 85-90.